Jesse Penico
Infectious Disease · Gulfport, MSNPI 1912904590
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,445 of the $49,410 with a category attached, or 71.7%. Paratek Pharmaceuticals, Inc. accounts for 84.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $27,035 and has fallen 77.1% since, to $6,190 in 2022. Among infectious disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $110.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$42K
- Viiv Healthcare Company$2K
- La Jolla Pharmaceutical Company$1K
- Astellas Pharma US Inc$658
- Merck$628
- Gilead$594
- plus $3K from 23 others
Across 5 payments — averaging $18,334 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$92K
What the payments were for
- Consulting fees$1,5303%
- Speaking & faculty fees$35,44572%
- Travel & lodging$3,0176%
- Food & beverage$9,29019%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 59 | $41,680 |
| Viiv Healthcare Company | 75 | $1,616 |
| La Jolla Pharmaceutical Company | 15 | $1,362 |
| Astellas Pharma US Inc | 36 | $658 |
| Merck | 40 | $628 |
| Gilead | 30 | $594 |
| Insmed, Inc. | 36 | $504 |
| AbbVie(2 entities) | 28 | $426 |
| Johnson & Johnson(2 entities) | 25 | $345 |
| Melinta Therapeutics, LLC | 20 | $316 |
| Accelerate Diagnostics Inc. | 11 | $278 |
| Cumberland Pharmaceuticals, Inc. | 20 | $245 |
| Tetraphase Pharmaceuticals, Inc. | 16 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $161 |
| Theratechnologies Inc. | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| EMD Serono, Inc. | 3 | $36 |
| Intercept Pharmaceuticals, Inc. | 2 | $31 |
| Pfizer | 2 | $28 |
| Dova Pharmaceuticals | 1 | $25 |
| Mayne Pharma Commercial LLC | 1 | $23 |
| Seqirus USA Inc | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
| Advanced Oxygen Therapy Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,410 in reported general payments places this provider in the 95th percentile of 36 infectious disease providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Gulfport
- Jo DealJackson$9K
- Svenja AlbrechtJackson$5K
- Olatunji OluwatadeVicksburg$3K
- Satwinder SinghGreenville$2K
- Thompson LiddellHattiesburg$2K
- Rathel NolanJackson$2K
- Jason MossHattiesburg$2K
- Richard FlowersJackson$1K
- Senate AmusuHattiesburg$1K
- Ujjwal DharJackson$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.